209 related articles for article (PubMed ID: 17588357)
1. The role of mTOR inhibitors for treatment of sarcomas.
Mita MM; Tolcher AW
Curr Oncol Rep; 2007 Jul; 9(4):316-22. PubMed ID: 17588357
[TBL] [Abstract][Full Text] [Related]
2. Ridaforolimus in advanced or metastatic soft tissue and bone sarcomas.
Mita MM; Gong J; Chawla SP
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):465-82. PubMed ID: 23971829
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
Yoo C; Lee J; Rha SY; Park KH; Kim TM; Kim YJ; Lee HJ; Lee KH; Ahn JH
Invest New Drugs; 2013 Dec; 31(6):1602-8. PubMed ID: 24037083
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
Chan S; Scheulen ME; Johnston S; Mross K; Cardoso F; Dittrich C; Eiermann W; Hess D; Morant R; Semiglazov V; Borner M; Salzberg M; Ostapenko V; Illiger HJ; Behringer D; Bardy-Bouxin N; Boni J; Kong S; Cincotta M; Moore L
J Clin Oncol; 2005 Aug; 23(23):5314-22. PubMed ID: 15955899
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
Chawla SP; Staddon AP; Baker LH; Schuetze SM; Tolcher AW; D'Amato GZ; Blay JY; Mita MM; Sankhala KK; Berk L; Rivera VM; Clackson T; Loewy JW; Haluska FG; Demetri GD
J Clin Oncol; 2012 Jan; 30(1):78-84. PubMed ID: 22067397
[TBL] [Abstract][Full Text] [Related]
6. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
Sethi TK; Keedy VL
Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
[TBL] [Abstract][Full Text] [Related]
7. Addition of Everolimus Post VEGFR Inhibition Treatment Failure in Advanced Sarcoma Patients Who Previously Benefited from VEGFR Inhibition: A Case Series.
ElNaggar AC; Hays JL; Chen JL
PLoS One; 2016; 11(6):e0156985. PubMed ID: 27295141
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas.
Vemulapalli S; Mita A; Alvarado Y; Sankhala K; Mita M
Target Oncol; 2011 Mar; 6(1):29-39. PubMed ID: 21533543
[TBL] [Abstract][Full Text] [Related]
9. A role for maintenance therapy in managing sarcoma.
Ray-Coquard I; Le Cesne A
Cancer Treat Rev; 2012 Aug; 38(5):368-78. PubMed ID: 21843915
[TBL] [Abstract][Full Text] [Related]
10. Everolimus for the treatment of advanced renal cell carcinoma.
Amato R
Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
[TBL] [Abstract][Full Text] [Related]
11. New therapeutic strategies for soft tissue sarcomas.
von Mehren M
Curr Treat Options Oncol; 2003 Dec; 4(6):441-51. PubMed ID: 14585225
[TBL] [Abstract][Full Text] [Related]
12. Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies.
Dancey JE; Monzon J
Future Oncol; 2011 Jul; 7(7):827-39. PubMed ID: 21732754
[TBL] [Abstract][Full Text] [Related]
13. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.
Qi WX; Huang YJ; Yao Y; Shen Z; Min DL
PLoS One; 2013; 8(6):e65166. PubMed ID: 23785409
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.
Vincenzi B; Napolitano A; D'Onofrio L; Frezza AM; Silletta M; Venditti O; Santini D; Tonini G
Expert Opin Investig Drugs; 2011 Dec; 20(12):1685-705. PubMed ID: 22010859
[TBL] [Abstract][Full Text] [Related]
16. Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity?
Garrido-Laguna I; Janku F
J Clin Oncol; 2012 Mar; 30(8):892-3. PubMed ID: 22291080
[No Abstract] [Full Text] [Related]
17. Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.
Judson I; Scurr M; Gardner K; Barquin E; Marotti M; Collins B; Young H; Jürgensmeier JM; Leahy M
Clin Cancer Res; 2014 Jul; 20(13):3603-12. PubMed ID: 24714778
[TBL] [Abstract][Full Text] [Related]
18. [Chemotherapy of metastatic soft tissue sarcoma].
Le Cesne A
Presse Med; 1995 Sep; 24(26):1214-20. PubMed ID: 7567851
[TBL] [Abstract][Full Text] [Related]
19. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.
Judson I; Radford JA; Harris M; Blay JY; van Hoesel Q; le Cesne A; van Oosterom AT; Clemons MJ; Kamby C; Hermans C; Whittaker J; Donato di Paola E; Verweij J; Nielsen S
Eur J Cancer; 2001 May; 37(7):870-7. PubMed ID: 11313175
[TBL] [Abstract][Full Text] [Related]
20. The value of adjuvant chemotherapy in the management of sarcomas in children.
Donaldson SS
Cancer; 1985 May; 55(9 Suppl):2184-97. PubMed ID: 3884137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
